Search research articles
Contact Us
Filters
Showing results (261-270 of 281) with videos related to
Page
of 29
Sort By:
Nature Medicine
|
March 6, 2019
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Jun Wang, Jingwei Sun, Linda N Liu, et al.
Science Translational Medicine
|
December 13, 2019
PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
Xue Han, Matthew D Vesely, Wendy Yang, et al.
Journal of Neuroinflammation
|
October 25, 2008
Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection
Gretchen Hermes, James W Ajioka, Krystyna A Kelly, et al.
Cell
|
December 25, 2018
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang, Miguel F Sanmamed, Ila Datar, et al.
American Journal of Respiratory Cell and Molecular Biology
|
November 30, 2022
VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis
Sang-Hun Kim, Taylor S Adams, Qianni Hu, et al.
Cancer Research
|
March 20, 2012
Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells
Magali Terme, Evelyn Ullrich, Laetitia Aymeric, et al.
Nature Medicine
|
August 24, 2004
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Tyler J Curiel, George Coukos, Linhua Zou, et al.
Nature Medicine
|
April 22, 2003
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Tyler J Curiel, Shuang Wei, Haidong Dong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2010
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
Julie R Brahmer, Charles G Drake, Ira Wollner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2023
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R Brahmer, Charles G Drake, Ira Wollner, et al.
Page
of 29
Search research articles
Search
Showing results (261-270 of 281) with videos related to
Sort By:
Page
of 29
Nature Medicine
|
March 6, 2019
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Jun Wang, Jingwei Sun, Linda N Liu, et al.
Science Translational Medicine
|
December 13, 2019
PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
Xue Han, Matthew D Vesely, Wendy Yang, et al.
Journal of Neuroinflammation
|
October 25, 2008
Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection
Gretchen Hermes, James W Ajioka, Krystyna A Kelly, et al.
Cell
|
December 25, 2018
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang, Miguel F Sanmamed, Ila Datar, et al.
American Journal of Respiratory Cell and Molecular Biology
|
November 30, 2022
VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis
Sang-Hun Kim, Taylor S Adams, Qianni Hu, et al.
Cancer Research
|
March 20, 2012
Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells
Magali Terme, Evelyn Ullrich, Laetitia Aymeric, et al.
Nature Medicine
|
August 24, 2004
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Tyler J Curiel, George Coukos, Linhua Zou, et al.
Nature Medicine
|
April 22, 2003
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Tyler J Curiel, Shuang Wei, Haidong Dong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2010
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
Julie R Brahmer, Charles G Drake, Ira Wollner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2023
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R Brahmer, Charles G Drake, Ira Wollner, et al.
Page
of 29